Masakatsu Motomura
Overview
Explore the profile of Masakatsu Motomura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kitanosono H, Motomura M, Tomita H, Iwanaga H, Iwanaga N, Irioka T, et al.
Brain Nerve
. 2019 Feb;
71(2):167-174.
PMID: 30718446
A 63-year-old female who developed dizziness, diplopia and subsequent gait disturbance from September X-1 year was analyzed. The first neurological findings in May X year revealed cerebellar ataxia, weakness in...
12.
Nakajima H, Motomura M, Morikawa M, Ando T, Kawakami A, Tsujino A
Magn Reson Med Sci
. 2018 Nov;
18(3):181-183.
PMID: 30416177
No abstract available.
13.
Motomura M
Nihon Naika Gakkai Zasshi
. 2018 Aug;
104(9):1953-8.
PMID: 30160905
No abstract available.
14.
Nakamura R, Makino T, Hanada T, Terakawa M, Nagahira K, Yamate J, et al.
J Neuroimmunol
. 2018 May;
320:64-75.
PMID: 29759142
Many myasthenia gravis (MG) patients have auto-antibodies against the nicotinic acetylcholine receptor (nAChR), and monoclonal antibodies against the main immunogenic region (MIR) of nAChR can induce experimental autoimmune MG (EAMG)....
15.
Kitanosono H, Shiraishi H, Motomura M
Brain Nerve
. 2018 Apr;
70(4):341-355.
PMID: 29632282
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease of the neuromuscular junction. Approximately 50-60% of patients with LEMS have a tumor, most often small cell lung cancer (SCLC), making LEMS...
16.
Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, Motomura M
Ann N Y Acad Sci
. 2018 Jan;
1413(1):35-40.
PMID: 29377151
According to the 2014 Japanese clinical guidelines for myasthenia gravis, the most important priority in treatment is maintaining patients' health-related quality of life. Therefore, the initial treatment goal is defined...
17.
Nakajima M, Uchibori A, Ogawa Y, Miyazaki T, Ichikawa Y, Kaneko K, et al.
Intern Med
. 2018 Jan;
57(11):1645-1649.
PMID: 29321433
A 61-year-old woman who had smoked for 41 years developed subacute dizziness, ataxic gait, opsoclonus, and right visual impairment. She had right optic disc swelling and optic nerve gadolinium enhancement...
18.
Deguchi K, Matsuzono K, Nakano Y, Kono S, Sato K, Deguchi S, et al.
Intern Med
. 2018 Jan;
57(10):1455-1458.
PMID: 29321424
A 37-year-old man with anti-muscle-specific tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) presented with subacute progressive dysphagia and muscle weakness of the neck and bilateral upper extremities. Conventional immune-suppressive treatments...
19.
Takasugi J, Shimamura M, Koda T, Kishikawa T, Hanamoto A, Inohara H, et al.
Intern Med
. 2017 Nov;
57(4):587-590.
PMID: 29093415
Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome (PCD-LEMS) are usually associated with small-cell lung carcinoma (SCLC). PCD-LEMS with extrapulmonary non-SCLC tumors; however, has not been previously reported. A 78-year-old man...
20.
Makino T, Nakamura R, Terakawa M, Muneoka S, Nagahira K, Nagane Y, et al.
PLoS One
. 2017 Oct;
12(10):e0185976.
PMID: 29040265
The majority of patients with myasthenia gravis (MG), an organ-specific autoimmune disease, harbor autoantibodies that attack the nicotinic acetylcholine receptor (nAChR-Abs) at the neuromuscular junction of skeletal muscles, resulting in...